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doi:10.1016/j.jtcvs.2008.02.011Objective: Pulmonary arteriovenous malformations commonly develop in children
who have undergone a cavopulmonary anastomosis as part of the palliative sequence
for single-ventricle physiology.
Methods: We developed a rat model of cavopulmonary anastomosis that results in
pulmonary arteriovenous malformations that are angiographically and histologically
similar to the human condition. We used this model to analyze the gene expression
profile associated with pulmonary arteriovenous malformations developing after cav-
opulmonary anastomosis.
Results: Six Sprague–Dawley rats underwent right superior cavopulmonary anasto-
mosis, allowing the left lung to serve as a control. Total RNA was isolated from
each lung at death 8 months postoperatively and compared by using the Affymetrix
Rat Microarray RAE230 2.0 GeneChip (Affymetrix, Santa Clara, Calif). One hundred
thirty-seven genes demonstrated altered expression in the lungs after cavopulmonary
anastomosis compared with that seen in the control lungs: 55 (40%) genes demon-
strated increased expression, and 82 (60%) genes demonstrated decreased expression.
Modulation of genes associated with angiogenesis and vascular remodeling was
found, including angiopoietin-2, placental growth factor, several matrix metallopro-
teases, and several collagen subtypes. Genes with vasoactive properties, including
endothelin 1 and endothelin receptor type B, demonstrated altered gene expression.
Several members of the transforming growth factor b superfamily signaling pathway
also demonstrated altered expression.
Conclusions: These changes in gene expression might have causative implications for
pulmonary arteriovenousmalformations that develop after cavopulmonary anastomosis.
C
hildren born with single-ventricle physiology undergo a palliative operative se-
quencewith the goal of creating a partitioned circulation. The Fontan procedure
is the ultimate step in the sequence whereby all systemic venous blood is di-
rected to the pulmonary arteries while pulmonary venous blood supplies the systemic
arterial circulation. In current practice a superior cavopulmonary anastomosis (CPA),
which establishes the superior vena cava as the sole source of pulmonary blood flow,
is performed as an interval step before the Fontan procedure. At the time of the Fontan
procedure, systemic venous blood from the inferior vena cava is routed to the pulmo-
nary arteries, which completes partitioning of the circulation. This staged palliative ap-
proach with an interval CPA has been shown to improve outcomes for these children
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CPA 5 cavopulmonary anastomosis
ECM 5 extracellular matrix
ET 5 endothelin
MMP 5 matrix metalloproteinase
NPY 5 neuropeptide Y
PAVM 5 pulmonary arteriovenous malformation
RT-PCR 5 real-time polymerase chain reaction
TGF 5 transforming growth factor
TPA 5 tissue plasminogen activator
and is currently the standard of care for their management.
Pulmonary arteriovenous malformations (PAVMs) have
been found to develop in children after CPA; these lesions
act as an intrapulmonary right-to-left shunt causing progres-
sive cyanosis. There is evidence that PAVMs develop when
the superior vena cava serves as the sole source of pulmonary
blood flow because of a process characterized by abnormal
angiogenesis and vascular remodeling caused by the absence
of hepatic-derived factors directly perfusing the lungs; how-
ever, the exact cause of these lesions remains unknown.1-3
We have previously developed an animal model of experi-
mental CPA in rats that results in PAVMs that are angiograph-
ically and histologically similar to those occurring in human
subjects.4,5 The present study applies DNA microarray tech-
nology to this animal model to determine the profile of genetic
expression present in lung tissue after CPA. The results sug-
gest that modulation of a number of genes associated with an-
giogenesis, vascular remodeling, and control of vascular tone
might contribute to the development of PAVMs after CPA.
Materials and Methods
Rat Surgical Intervention
Six male Sprague–Dawley rats (200-300 g) underwent a right supe-
rior CPA, as previously described.5 Briefly, animals were intubated
and ventilated with a pressure-controlled ventilator (Kent Scientific,
Torrington, Conn) after intraperitoneal pentobarbital-induced anes-
thesia.A right anterolateral thoracotomywas performed, and the right
superior vena cava and right pulmonary artery were anastomosed, al-
lowing the left lung to serve as a control. Animals were killed 8 to 9
months postoperatively, at which time lung samples were immedi-
ately snap-frozen in liquid nitrogen. All animals used in this study re-
ceived humane care in compliance with the ’’Guide for the care and
use of laboratory animals.‘‘ This study was approved by the Institu-
tional Animal Care and Use Committee of the Cleveland Clinic.
RNA Isolation
Total RNA was isolated from frozen lung tissue by using the RNA-
queous Kit (Ambion, Austin, Tex), per the manufacturer’s instruc-
tions. Briefly, samples were pulverized in a prechilled mortar and
then mixed with Lysis/Binding Buffer, passed through a 25-gauge
needle and centrifuged. Samples were then combined with 64% eth-284 The Journal of Thoracic and Cardiovascular Surgery c Auanol, mixed, and drawn through a filter cartridge assembly by means
of centrifugation. Filters were washed with Wash Solution #1,
centrifuged, and washed twice with Wash Solution #2/3. RNA
was eluted in a total of 100 mL of Elution Solution. RNA concentra-
tions were determined by means of ultraviolet absorbance.
Expression Microarrays
Total RNA was prepared from lung tissue of 6 rats for both the right
(CPA) lung and the left (control) lung.5 RNA samples were pro-
cessed for use on the Rat Microarray RAE230 2.0 GeneChip (Affy-
metrix, Santa Clara, Calif), according to the manufacturer’s
protocol. Briefly, total RNA was used in a reverse transcription
reaction (SuperScript II; Life Technologies, Rockville, Md) to
generate first-strand cDNA. After second-strand synthesis, double-
stranded cDNAwas used in an in vitro transcription reaction to gen-
erate larger amplified amounts of biotinylated cRNA. After purifica-
tion and fragmentation, biotin-labeled cRNA was used to produce
a hybridization cocktail containing spiked transcript controls, which
was then loaded onto microarrays and hybridized. Standard posthy-
bridization washes and double-staining protocols were performed
by using an Affymetrix GeneChip Fluidics Station 450. Arrays
were then scanned with the high-resolution Affymetrix GeneChip
Scanner 3000. GeneChip hybridization reactions and data collection
were done at the Gene Expression Array Core Facility, Case West-
ern Reserve University, Cleveland, Ohio.
Data Analysis
To determine those genes with altered expression in the PAVM lung
samples, binary quantified comparisons were generated with Gene-
Chip Operating Software 1.3 (Affymetrix, Santa Clara, CA) to yield
signal intensities, detection cells, and comparative signal ratios
between CPA and control samples for each probe set. To test the
overall quality and reproducibility of those chips analyzed, we mon-
itored a number of quality control indices, which included %P
values (the percentage of detection calls designated P [for ‘‘pres-
ent’’] on a chip, which should typically be consistent across a sample
set 63%), background, scaling factor, and 30/50 signal intensity
ratios for reduced glyceraldehyde-phosphate dehydrogenase and
b-actin. Signal log ratios from the comparison data were converted
into simple fold-change values. Genes with a fold change of be-
tween 2 and22 were removed from further analysis, whereas those
genes with fold changes of $2 or #22 were collated and grouped
based on frequency of occurrence. Further restrictions were added to
the analysis by removing those genes that had an occurrence fre-
quency of less than 60%. These genes were then further grouped
into functional classifications based on known or implied biologic
and molecular functions by using the Database for Annotation,
Visualization, and Integrated Discovery (http://david.abcc.ncifcrf.
gov).6 The complete dataset for gene expression in this animal
model of PAVMs after CPA was submitted to the Gene Expression
Omnibus of the National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov/geo/) and is accessible through
Gene Expression Omnibus Series accession number GSE6212.
Verification of GeneChip Data by Means of
Relative/Real-time Polymerase Chain Reaction
Eleven genes were selected for validation by the relative/real-time
polymerase chain reaction (RT-PCR) based on either their large
fold change, as determined by means of GeneChip analysis, or theirgust 2008
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DTABLE 1. RT-PCR verification of genes with altered expression levels identified by means of GeneChip analysis
Sample Forward Reverse RT-PCR FC GC FC
ET-B agcggctacgggactctc ctgggcaggtgggaatc 21.79 22.1
Efnb1 attactacattacatcaacatcca tgcccaaccttcataacaa 21.95 22.1
Gapj4 tgtgtcagccgggagataaag ccatggggaggtagaagaaaac 21.48 22.4
Gl1pr gggcaattgctgacgggtggaact ccgagaggaaggctgatgtaggtg 22.09 226.0
Plat Gccctggtgctatgtct Gggtgccacggtaagtca 21.93 22.3
Ang-2 ccgatcttcctccagcccctaca Ccagcccaccctcctaccttcatc 5.31 4.3
Col18a1 accaccaccaccaccaccacagtt ggaagtcagccccacggataccac 1.80 3.9
Esm1 ttcggatggattgcaaggagact Ttggctgctgcatactggaagaa 10.33 4.0
MMP-2 gtggccaactacaacttcttcc Gtgacgtcgctccatactttta 1.47 2.3
Myh6 cgggaagggggcaaggtcact Tggctcatgcaggaaggtcag 3.62 422.8
Tnnt2 tgcgaaacaggatcaacgacaacc Attcacagggcaagggcacagg 1.83 49.1
Relative expression was calculated by using the 22DDCT method.7 Negative fold changes were calculated as follows: 1/(22DDCT). RT-PCR FC, Fold change de-
terminedbymeansofRT-PCR;GCFC, fold changedeterminedbymeansofGeneChip analysis;ET-B, endothelin receptor typeB;Efnb1, ephrinB1;Gja4, gap junction
membrane channel proteina4;Glp1r, glucagon-like peptide 1 receptor; Plat, tissue plasminogen activator;Ang-2, angiopoietin 2; Col18a1, collagen, type XVIII,a1;
Esm1, endothelial cell–specific molecule 1; MMP-2, matrix metalloproteinase 2 (Gelatinase A);Myh6, myosin heavy chain, polypeptide 6; Tnnt2, troponin 2.suspected involvement in angiogenesis and vascular biology (see
below). Total lung RNA, isolated as previously described, was re-
verse transcribed in a volume of 10 mL by using TaqMan Reverse
Transcription Reagent (Applied Biosystems, Foster City, Calif).
cDNA was diluted to a concentration of 2 ng/mL. Primers were
designed based on mRNA sequences obtained from GenBank by
using Lasergene Sequence Analysis Software (DNAStar, Inc, Mad-
ison, Wis; Table 1). Real-time reactions were carried out by using
Platinum SYBER Green quantitative PCR SuperMix-UDG with
ROX (Invitrogen, Carlsbad, Calif). Briefly, 13 SYBER Green
PCR Master Mix was combined with the appropriate primers and
10 ng cDNA to a volume of 25 mL. Reactions were carried out by
using the ABI Prism 7700 Sequence Detection System (Applied Bi-
osystems) with an initial UDG incubation (50C for 2 minutes) and
a Taq activation step (95C for 10 minutes) followed by an amplifi-
cation cycle (403, 95C for 15 seconds) at the appropriate opti-
mized temperature for each primer (for 1 minute), as determined
by previous experiments (data not shown). Expression fold changes
were calculated for each gene by using the 22DDCT method, as pre-
viously described, with 18S RNA as a normalizing control.7
Results
Gene Expression by Means of Genechip Analysis
A total of 18 samples (2 samples from the CPA lung and 1
sample from the control lung for each animal) were subjected
to GeneChip analysis. Two CPA samples that contained out-
lying %P values were removed from further analytic consid-
erations, which resulted in 16 total samples (10 CPA and 6
control samples) for comparison. PAVM replicates were
compared to evaluate GeneChip consistency and then com-
pared with control specimens to generate a list of genes
that demonstrated altered levels of expression. As described
in the Materials and Methods section, these results were an-
alyzed by a defined set of criteria in which the altered expres-
sion of a gene must have an absolute value fold change of at
least62.0 and an occurrence rate of 60% or greater. The list
of genes with altered expression meeting the criteria definedThe Journal of Thorabove were further evaluated for multiple gene occurrences
and expressed sequence tags, which, when identified, were
removed from further analysis. These criteria resulted in
the identification of 137 genes with significant modulation
in the CPA lungs compared with control lungs: 55 (40%)
of these genes demonstrated increased expression, and 82
(60%) genes demonstrated decreased expression. Modulated
genes were subsequently grouped into one of 4 classifica-
tions; according to these classifications, genes that demon-
strated significant increases in the CPA lung were involved
in growth and development (29%), adhesion/extracellular
matrix (ECM)/cell structure (26%), receptor activity/signal-
ing (18%), or other miscellaneous functions (27%). Genes
that demonstrated decreased expression were involved in
growth and development (17%), adhesion/ECM/cell struc-
ture (20%), receptor activity/signaling (36%), or other mis-
cellaneous functions (27%). The entire dataset for gene
expression in this animal model of PAVMs after CPA can
be found in the Gene Expression Omnibus of the National
Center for Biotechnology Information, as described in the
Materials and Methods section. For brevity, a selected set
of genes of interest with either increased or decreased expres-
sion are presented in Tables 2 and 3, respectively.
RT-PCR Verification of Genechip Data
As described above, 11 genes were selected for validation by
means of RT-PCR based on either their degree of predicted
fold change (eg, glucagon-like peptide 1 receptor, troponin
T2, andmyosin heavy chain, polypeptide 6) or their suspected
involvement in angiogenesis and vascular biology (eg, angio-
poietin-2 and endothelin [ET] receptor, type B). The direc-
tional fold change of each gene was confirmed in all 11
genes tested, with some variations noted in the fold-change
values demonstrated by means of RT-PCR compared with
values obtained by means of GeneChip analysis (Table 1).acic and Cardiovascular Surgery c Volume 136, Number 2 285
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DTABLE 2. Selected genes with increased expression, as determined by means of GeneChip analysis in the lungs of rats
after CPA
Gene function Accession no. Gene Description FC
Development/growth/
morphogenesis
NM_012676 Tnnt2 Troponin T2, cardiac 49.1
NM_022604 Esm1 Endothelial cell–specific molecule 1 4.0
NM_017239 Myh6 Myosin heavy chain, polypeptide 6 422.8
NM_053595.1 Pgf Placental growth factor 4.5
NM_013130 Smad1 SMAD, mothers against DPP homolog 1 (Drosophila) 3.4
AF370889 Tpm1 Tropomyosin 1, a 45.3
BI275292 Agpt2 Angiopoietin 2 4.3
NM_012715 Adm Adrenomedullin 2.6
Adhesion/ECM/structural NM_053963 Mmp12 Matrix metalloproteinase 12 3.0
NM_134452 Col5a1 Collagen, type V, a1 2.6
NM_017066 Ptn Pleiotrophin 3.6
U65656 Mmp2 Matrix metalloproteinase 2 2.3
BI285575 Col1a1 Collagen, type 1, a1 3.4
BI288582 Col18a1 Collagen, type XVIII, a1 3.9
Other AI407239 Myom2 Myomesin 2 22.6
BM386752 Col15a1 predicted Procollagen, type XV (predicted) (endostatin domain) 3.0
Genes were grouped into functional classifications based on known or implied biologic and molecular functions by using the Database for Annotation, Vi-
sualization, and Integrated Discovery (http://david.abcc.ncifcrf.gov)6 and are listed only once; however, many genes might have multiple functions that
are not listed. FC, Fold change.Variations in fold-change values between GeneChip and RT-
PCR might have been due to different methods of
normalization for each technique. GeneChip values were nor-
malized by using a ‘‘scaling factor’’ recommended by the
manufacturer to normalize signal intensities to an arbitrary
mean value for each individual chip, whereas samples ana-
lyzed by using RT-PCR were first normalized against 18s
RNA and then subsequently used to generate values indicat-
ing the relative change between the test and control samples,
thus yielding a complete andmore accurate fold-change value.
Discussion
The present study describes the use of DNA microarrays to
investigate gene expression profiles in lung tissue from an
animal model of PAVMs after experimental CPA. The devel-
opment of PAVMs after CPA has been a clinically recog-
nized phenomenon for more than 30 years; however, very
little is understood regarding the cause or true biologic nature
of this condition.1,3 Physiologically, these lesions create an
intrapulmonary right-to-left shunt that causes progressive
cyanosis. Interestingly, PAVMs also develop in patients
with advanced liver failure and normal cardiac anatomy
that histologically and physiologically appear to be similar
to PAVMs that develop after CPA. This condition in patients
with liver failure, termed the hepatopulmonary syndrome, is
reversible after liver transplantation.8 Although the exact
cause of PAVM development in these clinical settings is un-
known, these lesions appear to develop whenever ‘‘func-
tional’’ hepatic venous effluent no longer directly perfuses
the lungs as a result of surgical diversion (after CPA) or as286 The Journal of Thoracic and Cardiovascular Surgery c Authe result of liver failure. We and others have hypothesized
that PAVMs represent a form of abnormal vascular develop-
ment that can occur due to the absence of a hepatic-derived
inhibitor of vascular proliferation and growth.1,2,9 Therefore
our previous studies have focused specifically on understand-
ing the role of mediators of pulmonary angiogenesis and vas-
cular remodeling in lung tissue from affected children and
a rat model of this condition.4,5,10-13 In these previous studies
we found altered expression of mediators associated with an-
giogenesis and vascular remodeling by assays for mRNA,13
for tissue proteins,10,12 and for histologic analyses of vessel
number and morphology.4,11
In the animal model used in the present study, a unilateral,
right-sided CPA is performed, which results in PAVM devel-
opment limited to the right lung, allowing the left lung to
serve as a control. We have previously documented that
this model accurately reproduces the angiographic and histo-
logic manifestations seen in the human condition.5 As ex-
pected, the transcriptome in the shunted lung after CPA
was substantially different from the control lung: 137 genes
were substantially modulated, with the majority (60%) dem-
onstrating downregulation. Our previous work focused on
mediators of angiogenesis and vascular remodeling in this
condition. A number of pertinent genes concerned with these
processes demonstrated altered expression; for example, an-
giopoietin-2 (Ang-2) expression was increased in the CPA
lungs compared with that seen in the control lungs. Ang-2
is an endothelial cell–specific growth factor that binds the
tyrosine kinase with immunoglobulin and epidermal growth
factor homology domain receptor (Tie-2), thus antagonizinggust 2008
Tipps et al Surgery for Congenital Heart Disease
CH
DTABLE 3. Selected genes with decreased expression, as determined by means of GeneChip analysis, in the lungs of rats
after CPA
Gene function Accession no. Gene Description FC
Development/growth/morphogenesis NM_013151 Plat Plasminogen activator, tissue 22.3
AI230625 Efnb1 Ephrin B1 22.1
BE105541 Cyp26b1 Cytochrome P450, family 26, subfamily b, polypeptide 1 26.5
BF398206 Bmpr2 Bone morphogenic protein receptor, type II 22.5
NM_012561 Fst Follistatin 212.9
Adhesion/ECM/structural NM_080776 Mmp16 Matrix metalloproteinase 16 22.2
NM_021654 Gja4 Gap junction membrane channel protein a4 22.4
NM_022221 Mmp8 Matrix metalloproteinase 8 29.4
NM_031055 Mmp9 Matrix metalloproteinase 9 25.7
Receptor activity/signaling NM_022441 Acvrl1 Activin A receptor type II –like 1 22.5
NM_012548 Edn1 Endothelin 1 22.7
NM_012728 Glp1r Glucagon-like peptide 1 receptor 226
X57764 Ednrb Endothelin receptor type B 22.1
NM_012614 Npy Neuropeptide Y 26.6
NM_012685 Vipr1 Vasoactive intestinal peptide receptor 1 24
Other AI058709 Nostrin Nitric oxide synthase trafficking 22.9
Genes were grouped into functional classifications based on known or implied biologic and molecular functions by using the Database for Annotation, Vi-
sualization, and Integrated Discovery (http://david.abcc.ncifcrf.gov)6 and are listed only once; however, many genes might have multiple functions that
are not listed. FC, Fold change; ECM, extracellular matrix.angiopoietin-1 (Ang-1)–induced phosphorylation of Tie-2.
Ang-2 induces vessel destabilization in preparation for an-
giogenesis, is increased in areas of vascular remodeling,
and appears to assist in the activation of matrix metalloprotei-
nase (MMP) 2.14-16 This pattern of vascular destabilization
and branching associated with increased Ang-2 and MMP-2
expression might help to explain histologic changes that we
have observed in lung tissue of children with PAVMs after
CPA, namely the presence of increased numbers of large,
thin-walled vessels with complex branching patterns that
extend far into the periphery of the lung.4
The expression of a number of other genes associated with
angiogenesis, vascular remodeling, or both was found to be
significantly modulated in the present study, including
placental growth factor, insulin-like growth factors 3 and 5,
cadherin 13, endothelial cell–specific molecule 1 (Esm1), tis-
sue plasminogen activator (TPA), integrin-b4, and interleu-
kin 1b, as well as members of the transforming growth
factor (TGF) b superfamily (see below). An important find-
ing was the observed modulation of a relatively large number
of factors responsible for the turnover of the ECM, including
a number of MMPs demonstrating both upregulation (MMP-
2 and MMP-12) and downregulation (MMP-8, MMP-9, and
MMP-16) after CPA. In addition, other factors with potential
involvement in ECM turnover and tissue remodeling demon-
strated altered expression in the CPA lung with either upregu-
lation (mast cell peptidase 2, tissue factor pathway inhibitor
2, and nidogen 2) or downregulation (mast cell protease 8,
heparanase, serine protease inhibitor, clade A, member 1,
and granzyme A). Several collagen subtypes were upregu-
lated as well, including collagen, type I, a1; collagen, typeThe Journal of ThoV, a1; procollagen, type XV; and collagen, type XVIII, a1.
Increased expression of collagen XVIII is of particular
interest in that (along with collagen XV) it is a component
of the vascular basement membrane and serves as a precursor
of the angiogenic inhibitor endostatin.17 Increased turnover of
the ECM is in keeping with mechanisms of angiogenesis and
vascular remodeling that have been hypothesized to be of
importance in the development of PAVMs after CPA.1 In ad-
dition to the histologic finding of increased numbers of dilated
and thin-walled blood vessels in this condition, we found that
the basement membrane of these vessels appeared disorga-
nized and contained prominent collagen fibers.4
Results of the present study also suggest that the TGF-b su-
perfamily of related polypeptide growth factors might be an
important signaling pathway in the development of PAVMs
after CPA. Ligand binding of the family of TGF-b receptors
activates cytoplasmic signaling proteins, which then translo-
cate to the nucleus to regulate gene transcription and mediate
the effects of TGF-b activation.18 Of particular interest in the
present context, primary pulmonary hypertension and hered-
itary hemorrhagic telangiectasia, which might each manifest
PAVMs, are due to mutations in the genes encoding receptors
belonging to the TGF-b superfamily.19,20 In the present study
we found that several members of the TGF-b signaling path-
way were modulated, including the receptors activin A recep-
tor type II–like kinase 1 (Acvrl1) and bone morphogenic
protein receptor, type II (Bmpr2), as well as the downstream
cytoplasmic effector of this pathway, mothers against decap-
entaplegic homolog 1 (Drosophila; Smad1). Furthermore,
TGF-b–dependent mechanisms have been found to be re-
sponsible for accelerated turnover of components of theracic and Cardiovascular Surgery c Volume 136, Number 2 287
Surgery for Congenital Heart Disease Tipps et al
CH
DECM in processes such as angiogenesis and in certain disease
states of the lung such as asthma and emphysema.18 In fact,
TGF-b–dependent mechanisms could be responsible for the
altered expression we observed in factors associated with in-
creased turnover of the ECM, including MMP-2, MMP-8,
MMP-9, MMP-12, and MMP-16. Finally, TGF-b pathway–
dependent mechanisms might be responsible for collagen
deposition, leading to fibrotic changes observed in emphy-
sema18; as discussed above, collagen types I, V, and XVIII
were all upregulated in the present study.
The expression of a number of other factors associated
with mechanisms that have been hypothesized to be of im-
portance in the development of PAVMs after CPA were
found to be altered in the present study. For example, factors
associated with changes in or maintenance of vascular tone,
including neuropeptide Y (NPY), TPA, gap junction mem-
brane channel protein 4 (also known as connexin 37), adreno-
medullin, ET-1, and ET-B receptor demonstrated altered
expression in the present study. NPY, which appears to
play an important role in the control of vascular tone through
sympathetic-mediated vasoconstriction,21 demonstrated de-
creased expression. Sympathetic neurons that express NPY
have been reported to synthesize, transport, and store TPA,
which can then generate plasmin from plasminogen; plasmin
can cleave pro-MMPs yielding their active forms, which
could promote further ECM turnover.22 Adrenomedullin pri-
marily functions in adrenal development but also appears to
play a role in the maintenance of vascular tone, where it func-
tions as a potent vasodilator.23 Additionally, decreased ex-
pression of gap junction membrane channel protein 4 (or
connexin 37), which is involved in both the regulation of vas-
cular tone and the remodeling of injured endothelium, might
also suggest that vascular remodeling is ongoing in PAVM
development.24 Regarding the possible role of ET-1 in this
phenomenon, an ET-B receptor–deficient animal model has
been shown to develop pulmonary ‘‘vascular leak’’ and pul-
monary edema, which is presumably mediated by unopposed
action of ET-1 on ET-A receptors through a vascular endo-
thelial growth factor–dependent mechanism.25 Serous pleu-
ral effusions are a well-recognized clinical problem after
CPA, which occurs because of increases in the systemic ve-
nous pressure in the superior vena cava and its branches after
this procedure; however, this study suggests that a molecular
mechanism mediated by an ET regulatory pathway might
also contribute to this phenomenon. Interestingly, we have
previously demonstrated histologic evidence of tissue edema
in the lungs of children after CPA, as well as ultrastructural
changes compatible with increased permeability in the pul-
monary capillaries that might corroborate the involvement
of ET, its receptors, or both.4
Finally, somegenes are present that appear to be clustered in
terms of function, suggesting their participation in potentially
important regulatory pathways that have no clear connection
with previously hypothesized mechanisms for PAVM devel-288 The Journal of Thoracic and Cardiovascular Surgery c Augopment. For example, the expressions of several myocardial
muscle proteins were upregulated, including troponin T2, my-
osin heavy chain polypeptide 6, tropomyosin-1a, and myome-
sin-2. The significance of this pattern of gene expression in the
lungs afterCPA isunclear at present but represents another pos-
sible pathway to be explored in the future.
A number of possible limitations exist in the present study.
Although altered expression determined by microarray anal-
ysis was verified for selected genes by using RT-PCR, expres-
sion for any gene of interest should be similarly verified by
using an alternate method before definite conclusions are
made. In addition, because of posttranslational modifications,
protein levels and therefore the biologic effect might differ
from measured RNA expression or the protein might be pres-
ent in inactive or modified forms (eg, MMPs, which might be
present in pre-, pro-, and active forms). System-related errors
can contribute to erroneous interpretation of these data; for ex-
ample, significant expression changes might be present for
a given gene that does not meet the analytic criteria used,
which would then be interpreted as unaltered gene expression
compared with control values. Another potential limitation
arises because of the diverse cell types present in the analyzed
samples; measured alterations in gene expressionmight come
from cell types not involved in PAVM development. Finally,
the limitations of the animal model in accurately reproducing
the human condition must be kept in mind. In the human con-
dition significant underlying congenital heart disease always
exists, whereas these animals have normal cardiopulmonary
status before surgical intervention. To validate the present re-
sults in an animal model, we are currently proceeding with
a similar analysis in human lung specimens in children with
PAVMs after CPA and healthy control subjects.
We thank Drs E. Plow and S. Erzurum for their professional
assistance and suggestions in the preparation of this manuscript.
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Discussion
Dr Frank W. Sellke (Boston, Mass). This is a very nice study in
a series from the group looking at the potential causal effects leading
to the formation of arteriovenous connections in the lungs of patients
who have undergone this operation. I have several questions.
This was a unilateral model in which you performed the CPA on
one side and you used the opposite, or normally perfused, lung as
a control. Is that correct?The Journal of ThorDr Duncan. That is correct.
Dr Sellke. Well, there are other factors involved such that the
perfusion to the control lung might not be quite normal. Would
you consider performing another control just to verify that there
are not additional changes going on in the control lung that ordinar-
ily would not occur?
Dr Duncan. Yes, I think that is a valid point. I think that might
be an important control group, especially as we go from general
pathways to specific factors. A particular problem with this expres-
sion profile technique arises from the great number of multiple com-
parisons, although it does provide a baseline to start. But certainly
going forward, as we look at more specific gene products, I think
that is a very good point.
Dr Sellke. What do you think the actual mechanism is? Is it the
changes in shear stress or absolute pressure? Do you have any idea
what might be causing these?
Dr Duncan. It certainly appears to be a complex process, a true
multifactorial process. The direct answer to your question is prob-
ably yes, and each factor you named probably contributes. Cer-
tainly there does appear to be the presence of a hepatic-derived
inhibitor, potentially in the hepatic venous effluent, that might par-
tially control pulmonary vascular development, even in the normal
state.
We see the effect of the liver on the pulmonary vasculature in
these patients because the CPA isolates the pulmonary arteries
from direct hepatic venous perfusion. However, I think it is overly
simplistic to say that this hepatic factor is the only causative factor
involved. Certainly effects related to alterations in shear stress after
CPA might be important; we have done some preliminary work that
shows this might play a causative role as well.
Dr Sellke. Listening to your talk and reading the paper, which
you gave me quite a while ago, you only examined gene expression
at 8 months, yet in disease processes and when you alter perfusion,
you can have immediate and midterm and long%2011term effects.
Do you have any idea whether the 8-month expression examination
is reflective of the actual mechanism causing the atrioventricular
malformations?
Dr Duncan. In our original published description of the model,
we reported our attempts at a quantitative assessment of this phe-
nomenon over time. We looked at microvessel density as a quantita-
tive indicator of angiogenesis. We found that the model does give
you a fairly linear relationship for microvessel density over time.
Applying DNA microarrays over time would be interesting; how-
ever, expense involved is the main limitation.
Dr Sellke. Finally, when you are looking at the cDNA micro-
array tests, even very small changes in gene expression can be sta-
tistically significant but really have very little effect on translation
to proteins. Have you done studies looking at protein expression
to see whether the changes in gene expression really mean any-
thing?
Dr Duncan. Yes, we have; that is really where we started in this.
Our initial studies looked at protein expression by using immunohis-
tochemistry. The DNA microarrays have introduced us to a new
area. The data that we see here, particularly those suggesting that
factors related to the ECM are important, have given us new areas
to explore. We are now going back and trying to corroborate these
findings in gene expression with changes in protein expression for
the MMPs and other ECM components.acic and Cardiovascular Surgery c Volume 136, Number 2 289
